Effect of multimodal analgesia on renal function and immune function of patients after renal transplantation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066447

Enrollment

Unknown

Registered

2022-12-06

Start date

2022-12-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage renal disease

Interventions

Multimodal analgesia group:Maintenance and postoperative analgesia induced by ketamine, 30 ml of 0.5 % ropivacaine for transverse abdominal fascia block and postoperative intravenous pump analgesia

transverse abdominal muscle fascia block group:Postoperative intravenous analgesia with 0.5 % ropivacaine 30 ml after anesthesia induction

Intravenous pump analgesia group:Postoperative intravenous pump analgesia

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65, no cognitive impairment, no severe cardiopulmonary disease, cardiac function II-III

Exclusion criteria

Exclusion criteria: Cognitive dysfunction, cardiac function above grade 3, decompensated pulmonary disease

Design outcomes

Primary

Measure	Time frame
pain score;PCA pressing effective times;recovery time;adverse reaction;IL-6;IL-10;CD4+;CD8+;CD4+/CD8+;NK cell;	—

Countries

China

Contacts

Public ContactYongguo Xie

The Second Affiliated Hospital of Guangxi Medical University

killiper@163.com+86 14795591217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026